1242156-76-8 Usage
General Description
The chemical "2-(6-(tert-butyl)-8-fluoro-1-oxophthalazin-2(1H)-yl)-6-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzyl acetate" is a complex compound with several functional groups. It contains a phthalazine ring system with a fluorine and tert-butyl substituent, as well as a boron-containing group and an acetate moiety. The compound likely has applications in synthetic chemistry, pharmaceutical development, or materials science due to the presence of the boron-containing group and the potential reactivity of the phthalazine ring system. It may have potential as a building block for the synthesis of more complex organic molecules or as a precursor for the development of new materials with specific properties.
Check Digit Verification of cas no
The CAS Registry Mumber 1242156-76-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,4,2,1,5 and 6 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1242156-76:
(9*1)+(8*2)+(7*4)+(6*2)+(5*1)+(4*5)+(3*6)+(2*7)+(1*6)=128
128 % 10 = 8
So 1242156-76-8 is a valid CAS Registry Number.
1242156-76-8Relevant articles and documents
INHIBITORS OF BRUTON'S TYROSINE KINASE
-
, (2015/04/22)
The disclosure includes compounds of Formula (I), wherein R0, R1, R2, R3, R4, R5, and L are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.
Inhibitors of Bruton's Tyrosine Kinase
-
Page/Page column 50-51, (2012/03/08)
This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y4, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
